LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Clinical trials for LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL explained in plain language.
Never miss a new study
Get alerted when new LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL trials appear
Sign up with your email to follow new studies for LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody therapy targets blood cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called JNJ-80948543 in people with non-Hodgkin lymphoma or chronic lymphocytic leukemia whose cancer has returned or not responded to other treatments. The drug works by redirecting the body's T-cells to attack cancer cells. The main goals …
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Cancer drug safety tracked in ongoing rollover trial
Disease control ENROLLING_BY_INVITATIONThis study monitors long-term safety in 120 cancer patients who are already benefiting from treatments like JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants have blood cancers, solid tumors, or prostate cancer. The goal is to track serious side effects over …
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can lower doses of ibrutinib still control CLL? new trial aims to find out
Disease control OngoingThis phase 2 study is testing whether adjusting the dose of ibrutinib—either by starting lower or reducing it when side effects occur—can still effectively control chronic lymphocytic leukemia (CLL) in people who have not yet been treated. Some participants will receive ibrutinib…
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Immune cell therapy takes on tough blood cancers
Disease control OngoingThis study tests a treatment called JCAR017, a type of CAR T-cell therapy, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, which are modi…
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE1, PHASE2 • Sponsor: Juno Therapeutics, a Subsidiary of Celgene • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug cocktail shows promise in battling blood cancer
Disease control OngoingThis phase 3 study tests whether a combination of two targeted drugs, ibrutinib and venetoclax, works better than the current standard therapy (chlorambucil plus obinutuzumab) for adults with chronic lymphocytic leukemia (CLL) who have not yet been treated. The main goal is to se…
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Blood cancer drug safety tracked over 5 years
Disease control OngoingThis study looks at the long-term safety of the drug pirtobrutinib in people with certain blood cancers, like chronic lymphocytic leukemia or non-Hodgkin lymphoma. It includes 13 participants who already benefited from the drug in an earlier study and will continue treatment ever…
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New CLL strategy: give extra drug only to those who still have cancer cells
Disease control OngoingThis phase 2 trial tests a personalized approach for chronic lymphocytic leukemia (CLL). Patients first receive two oral drugs (zanubrutinib and venetoclax). Only those who still have detectable cancer cells after treatment get an additional infusion drug (obinutuzumab). The goal…
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC